These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Utility of Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718 [No Abstract] [Full Text] [Related]
6. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer. Bach-Gansmo T; Korsan K; Bogsrud TV Tomography; 2022 Jun; 8(3):1477-1484. PubMed ID: 35736868 [TBL] [Abstract][Full Text] [Related]
7. Effect of hormonal therapy on Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974 [TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
9. Imaging Glioblastoma With Scarpelli ML; Healey DR; Mehta S; Quarles CC Front Oncol; 2022; 12():829050. PubMed ID: 35174096 [TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of Friedrich NA; Gu L; Waller J; De Hoedt AM; Klaassen Z; Freedland SJ Prostate; 2024 Oct; 84(14):1336-1343. PubMed ID: 39031050 [TBL] [Abstract][Full Text] [Related]
11. Exploratory Analysis of Serial Fatania K; Frood R; Tyyger M; McDermott G; Fernandez S; Shaw GC; Boissinot M; Salvatore D; Ottobrini L; Teh I; Wright J; Bailey MA; Koch-Paszkowski J; Schneider JE; Buckley DL; Murray L; Scarsbrook A; Short SC; Currie S Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884545 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Amino Acid/Drug Transporters for Renal Transport of [ Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421 [TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
14. A PET/MRI study towards finding the optimal [ Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158 [TBL] [Abstract][Full Text] [Related]
15. Mesci A; Ahmadi E; Ali A; Gouran-Savadkoohi M; Evelyn Tsakiridis E; Biziotis OD; Chow T; Kapoor A; Sur M; Steinberg GR; Liu S; Zukotynski K; Tsakiridis T Clin Transl Radiat Oncol; 2023 Mar; 39():100583. PubMed ID: 36713978 [TBL] [Abstract][Full Text] [Related]
16. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Sörensen J; Owenius R; Lax M; Johansson S Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of Teyateeti A; Teyateeti A; Ravizzini GC; Xu G; Tang C; Tu SM; Macapinlac HA; Lu Y Am J Nucl Med Mol Imaging; 2021; 11(2):87-98. PubMed ID: 34079638 [TBL] [Abstract][Full Text] [Related]